Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Sees Significant Growth in Short Interest

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) was the target of a large growth in short interest in August. As of August 31st, there was short interest totaling 34,223 shares, a growth of 797.8% from the August 15th total of 3,812 shares. Based on an average trading volume of 114,861 shares, the short-interest ratio is presently 0.3 days. Approximately 0.0% of the shares of the company are short sold.

Shionogi & Co., Ltd. Unsponsored ADR Price Performance

Shares of Shionogi & Co., Ltd. Unsponsored ADR stock opened at $9.14 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.14 and a quick ratio of 1.46. The company has a market cap of $15.56 billion, a PE ratio of 9.14, a price-to-earnings-growth ratio of 3.24 and a beta of 0.08. The firm has a fifty day moving average price of $8.97 and a two-hundred day moving average price of $9.60. Shionogi & Co., Ltd. Unsponsored ADR has a fifty-two week low of $7.65 and a fifty-two week high of $12.00.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) last posted its quarterly earnings data on Monday, August 3rd. The company reported $0.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.18 by $0.18. The company had revenue of $1.04 billion for the quarter, compared to the consensus estimate of $970.69 million. Shionogi & Co., Ltd. Unsponsored ADR had a net margin of 46.67% and a return on equity of 16.13%. Analysts expect that Shionogi & Co., Ltd. Unsponsored ADR will post 0.82 EPS for the current year.

Analysts Set New Price Targets

SGIOY has been the topic of several recent analyst reports. Zacks Research upgraded shares of Shionogi & Co., Ltd. Unsponsored ADR from a “strong sell” rating to a “hold” rating in a report on Monday, May 25th. Jefferies Financial Group upgraded Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, July 14th. Finally, The Goldman Sachs Group raised Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong-buy” rating in a report on Monday, June 15th. Two research analysts have rated the stock with a Strong Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Shionogi & Co., Ltd. Unsponsored ADR has a consensus rating of “Buy”.

About Shionogi & Co., Ltd. Unsponsored ADR

Shionogi & Co, Ltd. is a Japan-based pharmaceutical company that researches, develops, manufactures and markets prescription medicines. Founded in Osaka in 1878, the company has built its business around drug discovery and has a particular focus on infectious diseases, including antiviral and antibacterial treatments.

Shionogi’s products include Xofluza (baloxavir marboxil), an oral treatment for influenza, and Fetcroja (cefiderocol), an antibiotic used for certain difficult-to-treat bacterial infections.